P-ckit-ALLO1 / Roche - LARVOL DELTA

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PRNewswire) - The Company plans to present additional updates on both trials at a medical conference in 2023. The Company will present preclinical data on additional emerging allogeneic CAR-T programs including P-CD19CD20-ALLO1, P-CD70-ALLO1 and P-ckit-ALLO1.

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PRNewswire) - "Poseida Therapeutics, Inc....announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT....Allogeneic Cell Therapy Programs: The Company will recap early clinical data presented at the European Society for Medical Oncology Immuno-Oncology Annual Congress in December 2022 (ESMO I-O) on both of its Phase 1 allogeneic cell therapy programs: P-MUC1C-ALLO1, a wholly-owned CAR-T product candidate targeting solid tumors derived from epithelial cells, including breast and ovarian cancers, and P-BCMA-ALLO1, a CAR-T product candidate partnered with Roche targeting relapsed/refractory multiple myeloma. The Company plans to present additional updates on both trials at a medical conference in 2023. The Company will present preclinical data on additional emerging allogeneic CAR-T programs including P-CD19CD20-ALLO1, P-CD70-ALLO1 and P-ckit-ALLO1."

P1 data • Preclinical • Breast Cancer • Gynecologic Cancers • Hematological Malignancies • Multiple Myeloma • Oncology • Ovarian Cancer • Solid Tumor

Anti-c-kit CAR-T Cells Enable HSC Engraftment in a Humanized Model of Stem Cell Transplant Conditioning (ASGCT 2022) - "Conditioning regimens typically consist of high doses of genotoxic radiation or busulfan that can lead to life-threatening post-transplant complications. Our data indicate that anti-c-kit CAR-T cells can be used as an alternative and less toxic conditioning regimen to facilitate engraftment of autologous HSCs. Future studies aim to further develop our humanized transplant model to assess their use in an allogeneic HSC transplant setting."

CAR T-Cell Therapy • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD33 • CD34 • KIT • THY1

Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting (PRNewswire) - "Poseida Therapeutics, Inc...will present preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting....Data demonstrated that P-ckit-ALLO1 was able to eliminate 95% of HSCs in bone marrow within four days, which was sufficient to enable HSC transplant in a humanized mouse model with reduced acute myelotoxicity compared to busulfan. In addition, data demonstrated that P-ckit-ALLO1 was able to significantly inhibit growth of AML cells in animal models and significantly prolong survival."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (PRNewswire) - "Poseida Therapeutics...announced that preclinical data highlighting the use of anti-c-kit CAR-T cells, P-ckit-ALLO1 as a preconditioning agent to enable hematopoietic stem cell (HSC) transplants, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting....The Company's anti-c-kit CAR-T program leverages its proprietary piggyBac® Gene Delivery System and Cas-CLOVER™ Site-specific Gene Editing System to develop fully allogeneic CAR-T cells targeting human c-kit which is highly expressed on HSCs, as well as on myeloid malignancies such as acute myeloid leukemia (AML), meaning the treatment can be used for either HSC transplant conditioning or as a treatment for AML."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 (PRNewswire) - "The Company gave multiple oral and poster presentations earlier today, May 11, 2021, at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting...Two additional presentations highlighted preclinical data supporting Poseida's first allogeneic CAR-T product candidate, P-BCMA-ALLO1 for R/R multiple myeloma, as well as preclinical data supporting the Company's anti-c-kit CAR-T program as a potentially safer preconditioning regimen for hematopoietic stem cell transplantation in patients with AML."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma

[VIRTUAL] Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning (ASGCT 2021) - "These conditioning regimens typically consist of high doses of genotoxic radiation or busulfan that can lead to life-threatening post-transplant complications. To compare the activity of CAR 1 and CAR 2 in a transplant model we are currently performing a full allogeneic transplant study in huNSG mice involving CAR-T cell-mediated depletion of engrafted human stem cells, safety switch activation to clear the CAR-T cells, followed by engraftment of second donor CD34+ cells. We anticipate our results will provide additional strong evidence for use of stem cell-directed CAR-T cells as an alternative and less toxic conditioning regimen to facilitate engraftment of allogeneic and gene-corrected autologous HSCs and to significantly broaden the number of patients eligible for transplant."

CAR T-Cell Therapy • Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD34 • KIT • PTPRC

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting (PRNewswire) - "Poseida Therapeutics...announced three data presentations to be delivered at the upcoming American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, being held virtually May 11-14, 2021."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology